CN109009566B - Artificial crystal - Google Patents
Artificial crystal Download PDFInfo
- Publication number
- CN109009566B CN109009566B CN201810997274.0A CN201810997274A CN109009566B CN 109009566 B CN109009566 B CN 109009566B CN 201810997274 A CN201810997274 A CN 201810997274A CN 109009566 B CN109009566 B CN 109009566B
- Authority
- CN
- China
- Prior art keywords
- capsular
- optical zone
- adhesion structure
- capsular adhesion
- loop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title description 40
- 230000001727 anti-capsular Effects 0.000 claims abstract description 111
- 230000003287 optical effect Effects 0.000 claims abstract description 107
- 210000001742 aqueous humor Anatomy 0.000 claims abstract description 25
- 239000002775 capsule Substances 0.000 claims description 22
- 230000000149 penetrating effect Effects 0.000 claims description 22
- 230000007246 mechanism Effects 0.000 claims description 3
- 239000012528 membrane Substances 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 8
- 208000035965 Postoperative Complications Diseases 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 12
- 238000002513 implantation Methods 0.000 description 10
- 238000006073 displacement reaction Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 210000001542 lens epithelial cell Anatomy 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000007943 implant Substances 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 2
- 206010036346 Posterior capsule opacification Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
Abstract
The invention relates to the technical field of medical instruments, in particular to an artificial lens, which comprises a lens body, wherein the lens body comprises an optical area (1) and a loop (2), and is characterized by further comprising an anti-capsular adhesion structure (3) arranged outside the edge of the optical area (1), two end faces of the anti-capsular adhesion structure (3) are respectively contacted with a front capsular sac and a rear capsular, the anti-capsular adhesion structure (3) and the lens body are integrally formed, and two end faces of the optical area (1) are not beyond two end faces of the anti-capsular adhesion structure (3). The artificial lens provided by the invention has reasonable structural design, can prevent the lens body from being in direct contact with the front and rear capsular membranes, and has the function of promoting the circulation of aqueous humor in the capsular bag, so that PCO and ACO after operation can be effectively prevented, the operation process can be effectively simplified, and the occurrence probability of postoperative complications can be greatly reduced.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to an artificial lens.
Background
Common complications after intraocular lens implantation into the human eye are postoperative capsular opacification (posterior capsule opacification, abbreviated PCO), anterior capsular opacification (anterior capsule opacifieation, abbreviated ACO), anterior capsular contracture, which are essentially caused by proliferation of residual Lens Epithelial Cells (LEC) in cataract surgery.
The most commonly used way to prevent post-operative PCO is to make the edge of the back surface of the crystalline optic zone sharp. The rear surface of the crystal optical area is closely attached to the rear capsule. The posterior capsule is bent and shrunk at the included angle of the edge of the optical zone, so that LEC cells are blocked from migrating and proliferating to the contact part of the optical zone and the posterior capsule, and PCO is prevented. Although the sharp angle formed by the edge of the rear surface of the optical zone greatly reduces the occurrence of PCO, the blocking effect on ACO is poor, and PCO still has a certain occurrence rate, especially for crystals in the implantation period of more than 3 years. At present, the occurrence of PCO is reduced by adopting a sharp included angle in the crystal in the market, and a certain clinical effect is obtained, but the occurrence rate of PCO is still higher for a long time, and the PCO needs to be further reduced by a new crystal design.
According to the latest mechanism discovery about PCO: the aqueous humor circulation in eyes, the prevention of the adhesion of the capsular bag front and back and the adhesion of the lens and the capsular bag front and back can effectively prevent PCO. Based on this finding, the following design concept appears.
1. An anti-capsular adhesion ring as disclosed in document Toshiyuki Nagamoto,MD;Nobushige Tanaka,MD;Takaaki Fujiwara,MD.Inhibition of Posterior Capsule Opacification by a Capsular Adhesion–Preventing Ring.Arch Ophthalmol.2009;127(4):471-474.
The structure of the anti-capsular adhesion ring 1 'is shown in figure 1, the structure is a thin-wall structure with the diameter of 8.5mm and the height of 2.0mm, a small hole 2' (hole) capable of freely flowing aqueous humor is arranged on the thin wall, and an opening 3 '(groove) is arranged at the upper edge (contacted with the anterior capsule) for placing a crystal loop 4'.
In the operation, a doctor firstly implants the anti-capsular adhesion ring 1' for a patient, after placing the anti-capsular adhesion ring in place, then implants the existing artificial lens for the patient, clamps/puts the artificial lens into the ring to form a structure shown in figure 2, and the capsular bag is supported by the ring, so that the front and rear capsular films of the capsular bag are separated, adhesion does not occur any more, and adhesion does not occur between the capsular film and the optical surface of the lens. Aqueous humor can enter the crystal optic face region to prevent PCO from occurring. Meanwhile, through the small holes 2 'on the ring, the exchange of aqueous humor can be realized, and the aqueous humor environment can be formed in the area of the crystal loop 4'. A gap is formed between the crystal optical part and the ring, so that exchange and filling of aqueous humor can be realized.
However, this product has the following problems:
① The anti-capsular adhesion ring and the crystals are respectively two different products, the operation process is complex, and the implantation is inconvenient;
② The loop of the crystal is correctly placed into the opening of the anti-capsular adhesion ring in the eye and is well fixed, which is very difficult;
③ As the designs of the crystal loop are various, different crystals need different opening designs, and the crystal loop has no universality;
④ The anti-capsular adhesion ring lacks support in the eye and may be subject to misalignment.
2. Such as a disc crystal as disclosed in document Lisa Leishman,MD,Liliana Werner,MD,PhD.Prevention of capsular bag opacification with a modified hydrophilic acrylic disk-shaped intraocular lens.J Cataract Refract Surg 2012;38:1664–1670.
The disc crystal 5' is structured as shown in fig. 3, with the intermediate portion being the crystal optic 6' and the peripheral portion being the crystal haptic 4' region. Wherein the outer edges of the haptics 4' are of a complete circular shape. The edges of the haptics 4' have inwardly extending channels 7' which channels 7' allow free flow of aqueous humor. The outer edges of the haptics 4' are thicker to permit separation of the anterior and posterior membranes. The through holes on the haptics 4' allow for circulation of aqueous humor in the front and back of the crystal (the haptic and optic regions). Thereby realizing the prevention of PCO after operation.
The product has the following problems: the crystal edge was perfectly circular with a size of 9.5mm. The edges of the human eye capsular bag are rounded and there are large differences between individuals. When the crystal diameter is larger than the capsule edge diameter, the crystals with complete round edges cannot be compressed, and are not suitable for implantation; when the crystal diameter is smaller than the capsular rim diameter, the crystal lacks support in the eye, and decentration or displacement occurs, with the risk of deteriorating imaging quality.
Therefore, how to improve the existing intraocular lens to overcome the above-mentioned drawbacks is a problem to be solved by those skilled in the art.
Disclosure of Invention
Aiming at the current state of the art, the technical problem to be solved by the invention is to provide the artificial lens which has reasonable structural design and strong universality, can effectively simplify the operation process and can greatly reduce the occurrence probability of the operation complications.
The technical scheme adopted for solving the technical problems is as follows:
The utility model provides an intraocular lens, includes the crystal body, the crystal body includes optical zone and loop, the intraocular lens is still including setting up prevent capsule adhesion structure outside the optical zone edge, prevent two terminal surfaces of capsule adhesion structure respectively with preceding capsule and back capsule contact, prevent capsule adhesion structure with the crystal body is integrated into one piece structure, two terminal surfaces of optical zone all do not surpass prevent two terminal surfaces of capsule adhesion structure.
Specifically, the anti-capsular adhesion structure, the loop and the optical area of the artificial lens are integrated, the artificial lens is directly implanted into the human eye during operation, the operation process is simplified, meanwhile, the loop of the lens provides enough supporting force, and the risk of eccentric displacement of the anti-capsular adhesion structure caused by lack of support in the eye is avoided; the two end surfaces of the optical area are not beyond the two end surfaces of the anti-capsular adhesion structure, namely the thickness of the optical area is not beyond the highest height of the anti-capsular adhesion structure, the optical area is suspended and hidden in the anti-capsular adhesion structure, and the two end surfaces of the optical area are not contacted with or incompletely attached to the front capsular and the rear capsular, so that the crystal optical area is suspended or partially suspended in the capsular bag, and the occurrence probability of postoperative complications is greatly reduced.
Preferably, the wall of the anti-capsular adhesion structure is provided with a penetrating structure for free circulation of aqueous humor, and the penetrating structure can be a through hole, a groove or other hollow structures so as to realize circulation exchange of aqueous humor in the capsular bag, and in addition, the volume of the anti-capsular adhesion structure can be reduced, raw materials are saved, the compressibility of the artificial lens is enhanced, and the artificial lens is easy to fold and implant for injection.
Preferably, the middle part of the outer wall and/or the inner wall of the anti-capsular adhesion structure is inwards sunken to form a certain angle with the optical axis, namely the cross section of the anti-capsular adhesion structure is in a shape with a narrow middle and wide two ends, and is convenient to fold so as to be implanted into human eyes through a tiny incision.
Preferably, the angle is 0-45 degrees, when the angle is 0 degrees, the outer wall and/or the inner wall of the anti-capsular adhesion structure are parallel to the optical axis, and when the angle is more than 45 degrees, the upper end face and the lower end face of the anti-capsular adhesion structure are too wide to be folded easily. When the angle is more than 0 DEG and less than 45 DEG, the cross section of the anti-capsular adhesion structure is in a shape with a narrow middle and wide two ends, and is convenient to fold so as to be implanted into human eyes through a tiny incision.
Preferably, the tail ends of the loop penetrate out of the anti-capsular adhesion structure, the loop is still compressible, and the loop can conform to pupil sizes of different sizes and has high universality.
Preferably, the anti-capsular adhesion structure is a ring structure which is positioned outside the optical area and is integrally formed with the optical area and the loop, and is not easy to rotate and decenter after being implanted into the human eye, thereby being safe and reliable.
In particular, when the anti-capsular adhesion structure is a circular ring structure, the haptics are C-shaped haptics, L-shaped haptics, triangular haptics, plate-shaped haptics or other shaped haptics, preferably C-shaped haptics or L-shaped haptics.
Preferably, a plurality of connecting parts are formed between the anti-capsular adhesion structure of the ring structure and the optical area, and the anti-capsular adhesion structure of the ring structure is not easy to rotate and decenter relative to the optical area after being implanted into the human eye, so that the anti-capsular adhesion structure is safe and reliable.
Preferably, the part of the anti-adhesion structure supporting the rear capsule membrane is in a complete ring shape, the part of the anti-adhesion structure supporting the front capsule membrane is in a complete ring shape or a discontinuous ring shape, the discontinuous ring shape is more beneficial to the implantation of crystals, and aqueous humor can flow freely through a gap part of the discontinuous ring shape.
Preferably, the anti-capsular adhesion structure is a convex part fixed on the loop, and the structure is compact and convenient to use.
In particular, when the anti-capsular adhesion structure is a protrusion, the haptics are C-shaped haptics, L-shaped haptics, triangular haptics, plate-shaped haptics or other shaped haptics, preferably triangular haptics.
Preferably, the distance from the convex part on each haptic to the center of the optical zone is equal, namely, the convex parts are positioned on the same circular ring, and because a plurality of haptics are evenly distributed at the edge of the optical zone, the convex parts are evenly distributed on the haptics, and by adopting the technical scheme, the stress of the convex parts is even, and the artificial lens is less prone to decentration.
Preferably, the anti-capsular adhesion structure is an inclined structure between the optic and the haptics.
In particular, when the anti-capsular adhesion structure is an inclined structure, the haptics are C-shaped haptics, L-shaped haptics, triangular haptics, plate-shaped haptics or other shaped haptics, preferably plate-shaped haptics.
Preferably, the tilting mechanism comprises a supporting front end face, a supporting rear end face, an inner tilting face and an outer tilting face, wherein the inner tilting face and the outer tilting face are used for connecting the supporting front end face and the supporting rear end face, the optical area is connected with the inner tilting face, and the loop is connected with the outer tilting face.
Specifically, the front end surface of the support is located outside the front end surface of the optical zone, and the rear end surface of the support is located outside the rear end surface of the optical zone, that is, the two end surfaces of the optical zone are located between the front end surface of the support and the rear end surface of the support. The outer diameter of the front end face of the support is smaller than that of the rear end face of the support.
Preferably, the support posterior face is coplanar with the posterior face of the haptic. The inner inclined surface comprises an inner upper inclined surface and an inner lower inclined surface, the inner lower inclined surface is parallel to the outer inclined surface, and the inner upper inclined surface is parallel to or intersects with the central axis of the optical zone. The front end of the inner upper inclined surface is connected with the front supporting end surface, the rear end of the inner upper inclined surface is connected with the front optical zone end surface, the front end of the inner lower inclined surface is connected with the rear optical zone end surface, and the rear end of the inner lower inclined surface is connected with the rear supporting end surface. When the inner upper inclined surface intersects with the optical zone central axis, the distance from the front end of the inner upper inclined surface to the optical zone central axis is greater than the distance from the rear end of the inner upper inclined surface to the optical zone central axis.
Preferably, the front end surface of the support is a plane or an intersecting line, and when the front end surface of the support is an intersecting line, the front end surface of the support is an intersecting line of the inner inclined surface and the outer inclined surface.
Preferably, the edge of the contact part between the anti-adhesion structure and the front and rear membranes is in a sharp angle structure. The posterior capsule is bent and shrunk at the sharp angle structure, so that LEC cells are blocked to migrate and proliferate to the contact part of the capsule adhesion preventing structure and the posterior capsule, and PCO after operation is more effectively prevented.
Preferably, the diameter of the optical zone is 5.5-6.0 mm, and the anti-capsular adhesion structure is located in a region with 2.25-5.0 mm of the outward radius of the center of the optical zone.
Preferably, the thickness of the edge of the optical area is 0.1-0.3 mm, and the thickness of the anti-capsular adhesion structure is 0.5-2.5 mm.
Compared with the prior art, the technical scheme of the invention has the following beneficial effects:
According to the artificial lens, the anti-capsular adhesion structure is arranged, the anti-capsular adhesion structure and the lens body are integrated into a structure, the optical area is suspended in the capsular bag, and the artificial lens system can be integrally implanted during operation, so that the complex process of implanting the artificial lens after the anti-capsular adhesion structure is implanted in place in the prior art is avoided, the operation process is simplified, and meanwhile, the risk of eccentric displacement caused by lack of support of the anti-capsular adhesion structure in the eye is avoided; the loop fixing the artificial lens in the eye can be still compressed to conform to pupil sizes of different sizes, so that the universality is strong; the edge of the cyst membrane adhesion prevention structure is a sharp angle edge, and is provided with a penetrating structure for free circulation of aqueous humor, so that complications such as PCO, ACO and the like after operation can be effectively prevented, and the use is safe and reliable; the cross section of the anti-capsular adhesion structure can be in a shape with a narrow middle and wide two ends, and the special design is favorable for folding the part and the crystal and implanting the part and the crystal into eyes, so that the caliber of a syringe used in implantation can be reduced as much as possible.
Drawings
FIG. 1 is a schematic diagram of a prior art anti-adhesion ring.
FIG. 2 is a schematic view showing the use state of the anti-adhesion ring of FIG. 1.
Fig. 3 is a schematic structural diagram of a disc crystal according to the prior art.
Fig. 4 is a schematic structural diagram of a first embodiment of the present invention.
Fig. 5 is a schematic structural diagram of another view according to an embodiment of the present invention.
Fig. 6 is a schematic structural diagram of a second embodiment of the present invention.
Fig. 7 is a schematic structural diagram of another view according to the second embodiment of the present invention.
Fig. 8 is a schematic structural diagram of a third embodiment of the present invention.
Fig. 9 is a schematic structural diagram of a third alternative view of the embodiment of the present invention.
Fig. 10 is a schematic structural diagram of a fourth embodiment of the present invention.
Fig. 11 is a schematic structural diagram of a fourth embodiment of the present invention.
Fig. 12 is a schematic structural diagram of a fifth embodiment of the present invention.
Fig. 13 is a schematic structural diagram of a fifth alternative view of the embodiment of the present invention.
Wherein, in the prior art, the anti-capsular adhesion ring 1', the small hole 2', the opening 3', the loop 4', the disc-shaped crystal 5', the crystal optical area 6', the channel 7'.
In the present invention, an optical zone 1, a haptic 2, an anti-capsular adhesion structure 3, a penetrating structure 4, a connecting member 5, a support front end surface 31, a support rear end surface 32, an inner inclined surface 33, an outer inclined surface 34, an inner upper inclined surface 331, and an inner lower inclined surface 332.
Detailed Description
For a further understanding and appreciation of the structural features and advantages achieved by the present invention, the following description will be presented in conjunction with the accompanying drawings, in which:
Embodiment one:
As shown in fig. 4, an intraocular lens comprises a lens body, wherein the lens body comprises an optical zone 1 and a loop 2, the intraocular lens further comprises an anti-capsular adhesion structure 3 arranged outside the edge of the optical zone 1, two end faces of the anti-capsular adhesion structure 3 are respectively contacted with a front capsular sac and a rear capsular sac, the anti-capsular adhesion structure 3 and the lens body are in an integrated structure, and two end faces of the optical zone 1 do not exceed two end faces of the anti-capsular adhesion structure 3.
In this embodiment, the loop 2 is a C-shaped loop, the anti-capsular adhesion structure 3 is a ring structure located outside the optical area 1 and integrally formed with the optical area 1 and the loop 2, the ring-shaped anti-capsular adhesion structure 3 is directly formed on the loop 2, and the end of the loop 2 passes through the anti-capsular adhesion structure 3. The tail ends of the loop 2 can be compressed and expanded, and can meet pupil sizes of different sizes, so that the artificial lens has strong universality.
In this embodiment, the wall of the anti-capsular adhesion structure 3 is provided with a penetrating structure 4 for allowing the aqueous humor to freely circulate in the capsular bag. The part of the annular anti-capsular adhesion structure 3 for supporting the rear capsular membrane is in a complete annular shape, the part of the anti-capsular adhesion structure 3 for supporting the front capsular membrane is in a discontinuous annular shape, as shown in fig. 4, a discontinuous annular notch can be used as a penetrating structure, the discontinuous annular shape is more favorable for preventing the folding of the capsular adhesion structure 3, the implantation of crystals is facilitated, and aqueous humor can freely flow through the discontinuous annular notch. Meanwhile, the penetrating structure is arranged on the anti-capsular adhesion structure 3, so that raw materials are saved. In fig. 4, the partial area of the anti-adhesion structure 3 is filled with a shadow, which is only for distinguishing the non-notched portion (shadow-filled area) from the notched portion of the anti-adhesion structure, but does not indicate that the shadow-filled area is different from the non-filled area, and has no other meaning.
In other embodiments, the portion of the circular anti-adhesion structure 3 supporting the rear capsular membrane is in a complete ring shape, and the portion of the anti-adhesion structure 3 supporting the front capsular membrane is also in a complete ring shape, and at this time, a through hole or other hollow structure can be formed on the wall of the anti-adhesion structure 3 as a penetrating structure for allowing the aqueous humor to freely circulate in the capsular bag.
In this embodiment, as shown in fig. 4, a plurality of connecting members 5 are formed between the capsular adhesion preventing structure 3 of the annular structure and the optical zone 1, and the connecting members are uniformly arranged, that is, the annular capsular adhesion preventing structure 3 is not only directly connected with the loop 2, but also connected with the optical zone through the connecting members 5, and the capsular adhesion preventing structure 3 of the annular structure is not easy to rotate and decenter relative to the optical zone 1 after being implanted into the human eye, so that the device is safe and reliable.
In other embodiments, the annular anti-capsular adhesion structures 3 are attached only to the haptics 2 and do not contact the optic 1.
In this embodiment, as shown in fig. 5, the middle parts of the outer wall and the inner wall of the anti-capsular adhesion structure 3 are recessed inward to form an angle with the optical axis, the angle is 0 ° to 45 °, and when the angle is greater than 0 °, the cross section of the anti-capsular adhesion structure 3 is in a shape with narrow middle and wide two ends, so that the anti-capsular adhesion structure 3 is folded, so that the anti-capsular adhesion structure 3 can be implanted into human eyes through a small incision. When the angle is larger than 45 degrees, the upper end face and the lower end face of the anti-capsular adhesion structure 3 are too wide to be folded easily. When the angle is more than 0 DEG and less than 45 DEG, the cross section of the anti-capsular adhesion structure is in a shape with a narrow middle and wide two ends, and is convenient to fold so as to be implanted into human eyes through a tiny incision. It should be noted that, when the angles between the outer wall and the inner wall of the capsular adhesion preventing structure 3 and the optical axis are 0 °, the outer wall and the inner wall are flat and do not concave inwards.
In other embodiments, the outer wall of the anti-capsular adhesion structure 3 is concave and the inner wall is flat, or the outer wall of the anti-capsular adhesion structure 3 is flat and the inner wall is concave.
In this embodiment, the edge of the portion of the capsular adhesion preventing structure 3 contacting the anterior capsular sac and the posterior capsular sac is in a sharp angle structure, so as to more effectively prevent the occurrence of post-operative PCO.
In this embodiment, the optical zone 1 has a diameter of 5.5mm to 6.0mm, and the anti-capsular adhesion structure 3 is located in a region of 2.25mm to 5.0mm from the center of the optical zone 1 to the outside radius. The thickness of the edge of the optical area 1 is 0.1-0.3 mm, and the thickness of the anti-capsular adhesion structure 3 is 0.5-2.5 mm.
The anti-capsular adhesion structure 3, the loop 2 of the artificial lens and the optical zone 1 are integrated, the artificial lens is directly implanted into the human eye during operation, the operation process is simplified, meanwhile, the loop 2 of the lens provides enough supporting force, and the risk of eccentric displacement of the anti-capsular adhesion structure 3 caused by lack of support in the eye is avoided; the two end surfaces of the optical zone 1 do not exceed the two end surfaces of the anti-capsular adhesion structure 3, namely the thickness of the optical zone 1 does not exceed the height of the highest part of the anti-capsular adhesion structure 3, the optical zone 1 is suspended and contained in the anti-capsular adhesion structure 3, the two end surfaces of the optical zone 1 are not contacted with or incompletely attached to the front capsular sac and the rear capsular sac, so that the crystal optical zone 1 is suspended or partially suspended in the capsular bag, and the penetrating structure is arranged to promote the flow of aqueous humor, thereby greatly reducing the occurrence probability of complications such as PCO, ACO and the like after operation.
Embodiment two:
as shown in fig. 6 and 7, an intraocular lens comprises a lens body, wherein the lens body comprises an optical zone 1 and a loop 2, and as an improvement of the present invention, the intraocular lens further comprises an anti-capsular adhesion structure 3 arranged outside the edge of the optical zone 1, two end faces of the anti-capsular adhesion structure 3 are respectively contacted with a front capsular sac and a rear capsular, the anti-capsular adhesion structure 3 and the lens body are in an integrated structure, and two end faces of the optical zone 1 do not exceed two end faces of the anti-capsular adhesion structure 3.
In this embodiment, the loop 2 is a triangular loop, the anti-capsular adhesion structure 3 is a protrusion fixed on the loop 2, the protrusion is directly formed on the loop 2, and the end of the loop 2 passes through the anti-capsular adhesion structure 3. The tail ends of the loop 2 can be compressed and expanded, and can meet pupil sizes of different sizes, so that the artificial lens has strong universality. The distance from the convex part on each tab 2 to the center of the optical zone 1 is equal, namely the convex parts are positioned on the same circular ring, and because the convex parts are evenly distributed on the edge of the optical zone 1, the convex parts are evenly distributed on the tab 2, the stress of the convex parts is even, and the artificial lens is not easy to eccentric.
In this embodiment, the walls of the anti-capsular adhesion structures 3 are non-porous or have other hollow structures, and since the haptics 2 are spaced around the optical zone 3, the anti-capsular adhesion structures 3 on the haptics 2 are also spaced, and aqueous humor can freely circulate through the gaps between the anti-capsular adhesion structures 3.
In other embodiments, the wall of the anti-capsular adhesion structure 3 is provided with a penetrating structure (not shown) for allowing free circulation of aqueous humor within the capsular bag. The wall of the anti-capsular adhesion structure 3, i.e. the protruding part, is provided with a through hole or other hollow structure as a penetrating structure (not shown) for allowing the aqueous humor to freely circulate in the capsular bag. The penetrating structure is favorable for preventing the membrane adhesion structure 3 from being folded, so that the implantation of crystals is facilitated, and aqueous humor can freely flow through the penetrating structure. Meanwhile, the penetrating structure is arranged on the anti-capsular adhesion structure 3, so that raw materials are saved.
In this embodiment, as shown in fig. 7, the middle parts of the outer wall and the inner wall of the anti-capsular adhesion structure 3 are recessed inward to form an angle with the optical axis, the angle is 0 ° to 45 °, and when the angle is greater than 0 °, the cross section of the anti-capsular adhesion structure 3 is in a shape with narrow middle and wide two ends, so that the anti-capsular adhesion structure 3 is folded, so that the anti-capsular adhesion structure 3 can be implanted into human eyes through a small incision. When the angle is larger than 45 degrees, the upper end face and the lower end face of the anti-capsular adhesion structure 3 are too wide to be folded easily. When the angle is more than 0 DEG and less than 45 DEG, the cross section of the anti-capsular adhesion structure is in a shape with a narrow middle and wide two ends, and is convenient to fold so as to be implanted into human eyes through a tiny incision. It should be noted that, when the angles between the outer wall and the inner wall of the capsular adhesion preventing structure 3 and the optical axis are 0 °, the outer wall and the inner wall are flat and do not concave inwards.
In other embodiments, the outer wall of the anti-capsular adhesion structure 3 is concave and the inner wall is flat, or the outer wall of the anti-capsular adhesion structure 3 is flat and the inner wall is concave.
In this embodiment, the edge of the portion of the capsular adhesion preventing structure 3 contacting the anterior capsular sac and the posterior capsular sac is in a sharp angle structure, so as to more effectively prevent the occurrence of post-operative PCO.
In this embodiment, the optical zone 1 has a diameter of 5.5mm to 6.0mm, and the anti-capsular adhesion structure 3 is located in a region of 2.25mm to 5.0mm from the center of the optical zone 1 to the outside radius. The thickness of the edge of the optical area 1 is 0.1-0.3 mm, and the thickness of the anti-capsular adhesion structure 3 is 0.5-2.5 mm.
Embodiment III:
As shown in fig. 8 and 9, an intraocular lens comprises a lens body, wherein the lens body comprises an optical zone 1 and a loop 2, and as an improvement of the present invention, the intraocular lens further comprises an anti-capsular adhesion structure 3 arranged outside the edge of the optical zone 1, two end faces of the anti-capsular adhesion structure 3 are respectively contacted with a front capsular sac and a rear capsular, the anti-capsular adhesion structure 3 and the lens body are in an integrated structure, and two end faces of the optical zone 1 do not exceed two end faces of the anti-capsular adhesion structure 3.
In this embodiment, the haptics 2 are plate-shaped haptics and the capsular adhesion preventing structure 3 is an inclined structure between the optical zone 1 and the haptics 2. The inclined structure is integrally formed with the optic zone and the haptics.
In this embodiment, the wall of the anti-capsular adhesion structure 3 is provided with a penetrating structure 4 for allowing the aqueous humor to freely circulate in the capsular bag, the penetrating structure 4 is communicated with the crystal optical zone, and the penetrating structure 4 divides the anti-capsular adhesion structure 3 into intermittent structures and simultaneously communicates the inner inclined plane 33 with the outer inclined plane 34. The wall of the anti-capsular adhesion structure 3, i.e. the inclined structure, is provided with a plurality of through grooves as penetrating structures for allowing the aqueous humor to freely circulate in the capsular bag, and in this embodiment, each inclined structure is provided with two through grooves extending to the loop 2 along the length direction thereof, so as to communicate the front surface and the rear surface of the loop 2. The penetrating structure is arranged to divide the anti-adhesion structure 3 into intermittent structures, so that the folding of the anti-adhesion structure 3 of the capsule membrane in the implantation process is facilitated, the implantation of crystals is facilitated, and aqueous humor can flow freely through the through grooves. Meanwhile, the penetrating structure is arranged on the anti-capsular adhesion structure 3, so that raw materials are saved.
In other embodiments, the penetrating structure 4 is a plurality of through holes or other hollow structures formed on the wall of the anti-capsular adhesion structure 3 and the haptic, and connects the inner inclined surface 33 and the outer inclined surface, and connects the front surface and the rear surface of the haptic 2.
In this embodiment, as shown in fig. 9, the tilting structure includes a support front end surface 31, a support rear end surface 32, and an inner tilting surface 33 and an outer tilting surface 34 connecting the support front end surface 31 and the support rear end surface 32, the optical zone 1 is connected to the inner tilting surface, and the haptics 2 are connected to the outer tilting surface 34. The support front end surface 31 is located outside the optical zone front end surface, and the support rear end surface 32 is located outside the optical zone rear end surface, i.e., both end surfaces of the optical zone are between the support front end surface 31 and the support rear end surface 32. The support front end surface 31 has an outer diameter smaller than that of the support rear end surface 32.
In this embodiment, the support posterior face 32 is on the same plane as the posterior face of the haptics 2. The inner inclined surface 33 includes an inner upper inclined surface 331 and an inner lower inclined surface 332, the inner lower inclined surface 332 being parallel to the outer inclined surface 34, and the inner upper inclined surface 331 being parallel to the optical zone central axis. The front end of the inner upper inclined surface 331 is connected to the support front end surface 31, the rear end of the inner upper inclined surface 331 is connected to the optical zone front end surface, the front end of the inner lower inclined surface 332 is connected to the optical zone rear end surface, and the rear end of the inner lower inclined surface 332 is connected to the support rear end surface 32.
In the present embodiment, as shown in fig. 9, the support front surface 31 is a plane.
In this embodiment, the optical zone 1 has a diameter of 5.5mm to 6.0mm, and the anti-capsular adhesion structure 3 is located in a region of 2.25mm to 5.0mm from the center of the optical zone 1 to the outside radius. The thickness of the edge of the optical area 1 is 0.1-0.3 mm, and the thickness of the anti-capsular adhesion structure 3 is 0.5-2.5 mm.
Embodiment four:
The difference between this embodiment and the third embodiment is that:
In this embodiment, as shown in FIGS. 10 and 11, the support posterior face 32 is on the same plane as the posterior face of the haptic 2. The inner inclined surface 33 includes an inner upper inclined surface 331 and an inner lower inclined surface 332, the inner lower inclined surface 332 being parallel to the outer inclined surface 34, and the inner upper inclined surface 331 being parallel to the optical zone central axis. The front end of the inner upper inclined surface 331 is connected to the support front end surface 31, the rear end of the inner upper inclined surface 331 is connected to the optical zone front end surface, the front end of the inner lower inclined surface 332 is connected to the optical zone rear end surface, and the rear end of the inner lower inclined surface 332 is connected to the support rear end surface 32.
In the present embodiment, the supporting front end surface 31 is an intersecting line, that is, the supporting front end surface 31 is an intersecting line of the inner inclined surface 33 and the outer inclined surface 34.
Fifth embodiment:
The difference between this embodiment and the third embodiment is that:
In this embodiment, as shown in fig. 12 and 13, the support posterior face 32 is on the same plane as the posterior face of the haptic 2. The inner inclined surface 33 includes an inner upper inclined surface 331 and an inner lower inclined surface 332, the inner lower inclined surface 332 being parallel to the outer inclined surface 34, the inner upper inclined surface 331 intersecting the optical zone central axis. The front end of the inner upper inclined surface 331 is connected to the support front end surface 31, the rear end of the inner upper inclined surface 331 is connected to the optical zone front end surface, the front end of the inner lower inclined surface 332 is connected to the optical zone rear end surface, and the rear end of the inner lower inclined surface 332 is connected to the support rear end surface 32. The distance from the front end of the inner upper inclined surface 331 to the optical zone center axis is greater than the distance from the rear end of the inner upper inclined surface 331 to the optical zone center axis. Namely, the front part of the inclined structure is provided with two inclined planes, namely an inner upper inclined plane 331 and an outer inclined plane 34, which are favorable for the adhesion of the anterior capsule and the capsule adhesion preventing structure 3, and the stability of the intraocular lens in the eye is improved.
In the present embodiment, the support front surface 31 is a plane.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; while the invention has been described in detail with reference to the foregoing embodiments, those skilled in the art will appreciate that modifications may be made to the techniques described in the foregoing embodiments, or that equivalents may be substituted for elements thereof; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (7)
1. The artificial lens comprises a lens body, wherein the lens body comprises an optical zone (1) and a loop (2), and is characterized by further comprising an anti-capsular adhesion structure (3) arranged outside the edge of the optical zone (1), wherein two end faces of the anti-capsular adhesion structure (3) are respectively contacted with a front capsular sac and a rear capsular sac, the anti-capsular adhesion structure (3) and the lens body are of an integrated structure, and two end faces of the optical zone (1) are not beyond two end faces of the anti-capsular adhesion structure (3);
the wall of the anti-capsular adhesion structure (3) is provided with a penetrating structure (4) for freely circulating aqueous humor in the capsular bag;
the middle part of the outer wall and/or the inner wall of the anti-capsular adhesion structure (3) is inwards sunken to form a certain angle with the optical axis;
the angle is 0-45 degrees;
the anti-capsular adhesion structure (3) is a circular ring structure which is positioned outside the optical area (1) and is integrally formed with the optical area (1) and the loop (2);
the anti-capsular adhesion structure (3) is a bulge fixed on the loop (2);
the distance from the convex part on each loop (2) to the center of the optical area (1) is equal,
The anti-capsular adhesion structure (3) is an inclined structure positioned between the optical zone (1) and the loop (2);
The tilting mechanism comprises a supporting front end face (31), a supporting rear end face (32), an inner tilting face (33) and an outer tilting face (34) which are used for connecting the supporting front end face (31) and the supporting rear end face (32), the optical zone (1) is connected with the inner tilting face, and the loop (2) is connected with the outer tilting face.
2. An intraocular lens according to claim 1, wherein the ends of the haptics (2) protrude from the capsular adhesion preventing structure (3).
3. An intraocular lens according to claim 1, wherein the portion of the capsular adhesion preventing structure (3) supporting the posterior capsule is of a complete ring shape, and the portion of the capsular adhesion preventing structure (3) supporting the anterior capsule is of a complete ring shape or of a discontinuous ring shape.
4. An intraocular lens according to claim 1, wherein the supporting anterior face (31) is a plane or an intersecting line.
5. An intraocular lens according to any one of claims 1 to 3, wherein the edge of the portion of the capsular adhesion preventing structure (3) contacting the anterior capsular bag and the posterior capsular bag is in a sharp angle structure.
6. An intraocular lens according to any one of claims 1 to 4, wherein the diameter of the optical zone (1) is 5.5-6.0 mm, and the capsular adhesion preventing structure (3) is located in a region of 2.25-5.0 mm radius outwards from the centre of the optical zone (1).
7. An intraocular lens according to any one of claims 1 to 4, wherein the thickness of the edge of the optical zone (1) is 0.1-0.3 mm and the thickness of the capsular adhesion preventing structure (3) is 0.5-2.5 mm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710753023 | 2017-08-29 | ||
| CN2017107530233 | 2017-08-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109009566A CN109009566A (en) | 2018-12-18 |
| CN109009566B true CN109009566B (en) | 2024-04-26 |
Family
ID=64625319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810997274.0A Active CN109009566B (en) | 2017-08-29 | 2018-08-29 | Artificial crystal |
| CN201821416208.1U Active CN209301398U (en) | 2017-08-29 | 2018-08-29 | A kind of artificial lens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201821416208.1U Active CN209301398U (en) | 2017-08-29 | 2018-08-29 | A kind of artificial lens |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN109009566B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109009566B (en) * | 2017-08-29 | 2024-04-26 | 东莞东阳光医疗智能器件研发有限公司 | Artificial crystal |
| CN109285191B (en) * | 2018-09-20 | 2019-07-19 | 郭涛 | The detection method and system of artificial lens |
| CN110215314A (en) * | 2019-05-21 | 2019-09-10 | 温州医科大学附属眼视光医院 | A kind of artificial lens |
| CN112198577B (en) * | 2019-10-23 | 2022-04-26 | 东莞东阳光医疗智能器件研发有限公司 | Ophthalmic lens |
| CN110811925A (en) * | 2019-12-13 | 2020-02-21 | 上海千健医药科技有限公司 | Intraocular lens for eye rehabilitation implantation |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1189872A (en) * | 1997-07-19 | 1999-04-06 | Toshiyuki Nagamoto | Lenticular capsule adhesion preventive ring |
| JP2002253585A (en) * | 2001-02-28 | 2002-09-10 | Canon Star Kk | Intraocular implant |
| CN101283933A (en) * | 2008-04-07 | 2008-10-15 | 崔浩 | Artificial crystalline lens of blocking eaves type limitation after cataract |
| JP2009196136A (en) * | 2008-02-20 | 2009-09-03 | Hoya Corp | Manufacturing method of intraocular lens |
| NL2001503C2 (en) * | 2008-04-21 | 2009-10-22 | Oculentis B V | Intraocular lens. |
| CN102090946A (en) * | 2011-02-17 | 2011-06-15 | 郝燕生 | Artificial intraocular lens capsular sac adopting loop filaments for intraocular fixing |
| CN202446299U (en) * | 2012-01-19 | 2012-09-26 | 爱博诺德（北京）医疗科技有限公司 | Posterior chamber intraocular lens |
| JP2013123616A (en) * | 2011-12-16 | 2013-06-24 | Chukyo Medical Co Inc | Intraocular lens |
| CN209301398U (en) * | 2017-08-29 | 2019-08-27 | 东莞东阳光医疗智能器件研发有限公司 | A kind of artificial lens |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3000435B1 (en) * | 2005-05-20 | 2017-09-13 | Kowa Company, Ltd. | Intraocular lens |
| US20080077238A1 (en) * | 2006-09-21 | 2008-03-27 | Advanced Medical Optics, Inc. | Intraocular lenses for managing glare, adhesion, and cell migration |
| US9486311B2 (en) * | 2013-02-14 | 2016-11-08 | Shifamed Holdings, Llc | Hydrophilic AIOL with bonding |
| WO2015012312A1 (en) * | 2013-07-24 | 2015-01-29 | 興和株式会社 | Intraocular lens-inserting instrument |
-
2018
- 2018-08-29 CN CN201810997274.0A patent/CN109009566B/en active Active
- 2018-08-29 CN CN201821416208.1U patent/CN209301398U/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1189872A (en) * | 1997-07-19 | 1999-04-06 | Toshiyuki Nagamoto | Lenticular capsule adhesion preventive ring |
| US6063118A (en) * | 1997-07-19 | 2000-05-16 | Nagamoto; Toshiyuki | Capsular adhesion preventing ring |
| JP2002253585A (en) * | 2001-02-28 | 2002-09-10 | Canon Star Kk | Intraocular implant |
| JP2009196136A (en) * | 2008-02-20 | 2009-09-03 | Hoya Corp | Manufacturing method of intraocular lens |
| CN101283933A (en) * | 2008-04-07 | 2008-10-15 | 崔浩 | Artificial crystalline lens of blocking eaves type limitation after cataract |
| NL2001503C2 (en) * | 2008-04-21 | 2009-10-22 | Oculentis B V | Intraocular lens. |
| CN102090946A (en) * | 2011-02-17 | 2011-06-15 | 郝燕生 | Artificial intraocular lens capsular sac adopting loop filaments for intraocular fixing |
| JP2013123616A (en) * | 2011-12-16 | 2013-06-24 | Chukyo Medical Co Inc | Intraocular lens |
| CN202446299U (en) * | 2012-01-19 | 2012-09-26 | 爱博诺德（北京）医疗科技有限公司 | Posterior chamber intraocular lens |
| CN209301398U (en) * | 2017-08-29 | 2019-08-27 | 东莞东阳光医疗智能器件研发有限公司 | A kind of artificial lens |
Non-Patent Citations (2)
| Title |
|---|
| 《Inhibition of Posterior Capsule Opacification by a Capsular Adhesion–Preventing Ring》;Toshiyuki Nagamoto, MD;《Arch Ophthalmol》;第第127卷卷(第第4期期);471-474页 * |
| 《Prevention ofcapsular bag opacification with a modified hydrophilic acrylic disk-shapedintraocular lens》;Lisa Leishman, MD;《J CATARACT REFRACT SURG》(第第38期期);第1664–1670页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN209301398U (en) | 2019-08-27 |
| CN109009566A (en) | 2018-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109009566B (en) | Artificial crystal | |
| CN108348327B (en) | Modular intraocular lens design, tools and methods | |
| CN109069267B (en) | Intraocular lens design for improved stability | |
| US20220331094A1 (en) | Modular intraocular lens designs, tools and methods | |
| US9421088B1 (en) | Modular intraocular lens designs, tools and methods | |
| US6881225B2 (en) | Intraocular lenses with a groove for closing the opening of the posterior capsule | |
| US20110313521A1 (en) | Intraocular rings and associated systems and methods | |
| US6235055B1 (en) | Intraocular lens having colored haptics for anterior/posterior orientation, and method for implanting it | |
| GB2124500A (en) | Improved fixation system for intraocular lens structures | |
| CN103006351A (en) | Intraocular lens | |
| US20210315687A1 (en) | Intraocular Artificial Lens Capsule | |
| CN111481322B (en) | Adjustable bag inner ring | |
| US6221106B1 (en) | Diaphragm for implantation in the lens capsule sac of an eye | |
| CN111467077B (en) | Comprehensive artificial lens implant for congenital cataract | |
| JPH0323857A (en) | Intraocular lens | |
| CN209548142U (en) | A kind of novel intraocular lens | |
| CN110811925A (en) | Intraocular lens for eye rehabilitation implantation | |
| CN203280538U (en) | Intraocular lens | |
| CN215778913U (en) | Foldable eccentric-resistant suspensible intraocular lens | |
| CN203280539U (en) | Intraocular lens | |
| CN219048979U (en) | Embryo structure for reducing PCO incidence rate | |
| CN114533341A (en) | Intraocular lens | |
| SU1271507A1 (en) | Artificial eye lens | |
| JP2023521389A (en) | A multi-part IOL with a stable IOL base design that supports the second optic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190729 Address after: 523871 Room 301, 3rd floor, 368 Zhenan Middle Road, Sha Community, Chang'an Town, Dongguan City, Guangdong Province Applicant after: Dongguan Dongyang Sunshine Medical Intelligent Device R&D Co.,Ltd. Address before: 523871 No. 368 Zhenan Middle Road, Chang'an Town, Dongguan City, Guangdong Province Applicant before: DONGGUAN HEC TECH R&D Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |